Aventis Builds U.S. Diabetes Portfolio On Strong Amaryl Performance
Executive Summary
Aventis is building its U.S. diabetes franchise in the near term based on strong sales of the oral sulfonylurea Amaryl, Investor Relations Director Arvind Sood said during a conference call July 28.